Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of “Hold” from Brokerages

Oncobiologics, Inc. (NASDAQ:OTLK) has been assigned an average rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $6.50.

Several research analysts have recently weighed in on OTLK shares. Chardan Capital reiterated a “neutral” rating on shares of Oncobiologics in a research note on Wednesday. Wall Street Zen downgraded Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Ascendiant Capital Markets boosted their price target on Oncobiologics from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, December 22nd. HC Wainwright reiterated a “neutral” rating on shares of Oncobiologics in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th.

Trending Headlines about Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Brookline Capital Acquisition raised its Q4 2026 EPS estimate for OTLK to ($0.18) from ($0.22), narrowing the expected quarterly loss — a modest positive signal that one shop sees slightly better near-term performance.
• Neutral Sentiment: HC Wainwright reiterated a “Neutral” rating on Oncobiologics while publishing updated quarterly/annual estimates; the firm remains cautious but did not upgrade or downgrade the stock. HC Wainwright Reaffirms “Neutral” Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: Chardan Capital reiterated its “Neutral” rating on OTLK, signaling no near-term change in analyst stance despite the earnings miss and estimate revisions. Chardan Capital Reiterates Neutral Rating for Oncobiologics (NASDAQ:OTLK)
• Negative Sentiment: HC Wainwright cut FY2026 estimates significantly (FY2026 EPS to ($0.42) from ($0.28)) and trimmed FY2027 to ($0.21) from ($0.19), and nudged Q4 2026 to a larger expected loss — these downward revisions signal weaker near-term profitability expectations and add selling pressure.
• Negative Sentiment: Brookline Capital Acquisition lowered multiple 2026 quarterly and full‑year EPS forecasts (e.g., FY2026 now ($0.79) vs. prior ($0.74); Q2/Q3 2026 also reduced), indicating broader analyst downside revisions across the board.
• Negative Sentiment: Oncobiologics’ recent reported miss (Feb. 17: EPS ($0.22) vs est. ($0.17); revenue sharply below expectations) remains the primary near-term catalyst weighing on the stock—analyst cuts followed the miss and are likely driving continued downward price pressure.

Oncobiologics Trading Down 4.9%

NASDAQ:OTLK opened at $0.41 on Friday. Oncobiologics has a 12 month low of $0.38 and a 12 month high of $3.39. The company has a market cap of $34.32 million, a PE ratio of -0.16 and a beta of 0.10. The company has a 50 day simple moving average of $0.90 and a two-hundred day simple moving average of $1.31.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The firm had revenue of ($1.21) million during the quarter, compared to analysts’ expectations of $3.14 million. Research analysts forecast that Oncobiologics will post -2.27 earnings per share for the current year.

Institutional Investors Weigh In On Oncobiologics

Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its position in shares of Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after buying an additional 44,063 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after acquiring an additional 21,941 shares during the last quarter. 11.20% of the stock is owned by hedge funds and other institutional investors.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.